Literature DB >> 12914214

[Dynamic observation of the features of chest radiograph in SARS patients].

Jing Ma1, Nan Li, Chengli Que, Haichao Li, Ligong Nie, Guangfa Wang, Zhidong Gao, Rengui Wang, Xiaoyuan Xu, Haiying Lu, Guiqiang Wang.   

Abstract

OBJECTIVE: To observe the radiological features of chest X ray in SARS patients.
METHODS: The chest films of 23 cases of SARS were reviewed in the study. The chest film features and site of lung involvement were studied in early stage, most severe stage and recovery stage. The sequential chest film were evaluated hemiquantitatively. The correlation between the score of lung involvement and clinical course was also studied.
RESULTS: The lung involvement was most common in lower lung field and outer zone both in early and acute stage. 91.3% cases had bilateral involvement and 91.2% had multifield involvement (two lung fields involvement is 47.8%, three and four lung fields involvement are both 21.7%). The ill-defined and variable opacities showed to be dominant. The improvement of acute stage lesion in 17 cases is related to the usage and increased dosage of corticosteroid, some cases showed non-parallel with symptom and chest X-ray. Hemiquantitative analysis showed there are 6 cases had second peak in X ray, the mean time of onset is 13.2 days, and lasted for 5.8 days.
CONCLUSION: The chest X ray of SARS has some features and its changes can reflect the clinical situation.

Entities:  

Mesh:

Year:  2003        PMID: 12914214

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  2 in total

1.  Current status of severe acute respiratory syndrome in China.

Authors:  Qing-He Nie; Xin-Dong Luo; Jian-Zhong Zhang; Qin Su
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

2.  Chest radiograph screening for severe acute respiratory syndrome in the ED.

Authors:  Stewart Siu-Wa Chan; Paulina Siu-Kuen Mak; Kwok Kuen Shing; Po Nin Chan; Wing Hung Ng; Timothy Hudson Rainer
Journal:  Am J Emerg Med       Date:  2005-07       Impact factor: 2.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.